R188e-SSSLipiodol : Development of a Potential Treatment for HCC from Bench to Bedside

الملخص EN

Hepatocellular carcinoma (HCC) is the 5th most common tumour worldwide and has a dark prognosis.

For nonoperable cases, metabolic radiotherapy with Lipiodol labelled with β-emitters is a promising therapeutic option.

The Comprehensive Cancer Centre Eugène Marquis and the National Graduate School of Chemistry of Rennes (ENSCR) have jointly developed a stable and efficient labelling of Lipiodol with rhenium-188 (Eβmax=2.1 MeV) for the treatment of HCC.

The major “milestones” of this development, from the first syntheses to the recent first injection in man, are described.